Compare · ARGX vs MAZE
ARGX vs MAZE
Side-by-side comparison of argenx SE (ARGX) and Maze Therapeutics Inc. (MAZE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and MAZE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 37.4x MAZE ($1.69B).
- Over the past year, ARGX is up 44.0% and MAZE is up 116.0% - MAZE leads by 72.0 points.
- MAZE has been more active in the news (12 items in the past 4 weeks vs 11 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 7 for MAZE).
- Company
- argenx SE
- Maze Therapeutics Inc.
- Price
- $1019.71+0.82%
- $30.41+2.72%
- Market cap
- $63.27B
- $1.69B
- 1M return
- +14.62%
- +5.81%
- 1Y return
- +43.97%
- +116.02%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2025
- News (4w)
- 11
- 12
- Recent ratings
- 25
- 7
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE
Latest MAZE
- SEC Form 4 filed by Director Kornowski Sophie
- SEC Form 4 filed by Director Johnson Paula A
- SEC Form 3 filed by new insider Kornowski Sophie
- SEC Form 3 filed by new insider Johnson Paula A
- Maze Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- President, R&D & CMO Bernstein Harold exercised 16,142 shares at a strike of $10.42 and sold $445,621 worth of shares (16,142 units at $27.61) as part of a pre-agreed trading plan (SEC Form 4)
- Maze Therapeutics Announces Appointments to Its Board of Directors
- SEC Form 10-Q filed by Maze Therapeutics Inc.
- Maze Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights